https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-07-01 / Anticancer Res 2021 Jul;41(7):3419-3427
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-07-01 / Anticancer Res 2021 Jul;41(7):3419-34272021-07-01 00:00:002023-03-07 11:15:55Prophylactic Dendritic Cell Vaccination in Experimental Breast Cancer Controls Immunity and Hepatic Metastases
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-06-29 / J Eur Acad Dermatol Venereol 2021 Oct;35(10):1976-1986
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-06-29 / J Eur Acad Dermatol Venereol 2021 Oct;35(10):1976-19862021-06-29 00:00:002021-06-29 00:00:00A Bayesian network meta-analysis of comparison of cancer therapeutic vaccines for melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-06-28 / Front Cell Dev Biol 2021;9:686544
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-06-28 / Front Cell Dev Biol 2021;9:6865442021-06-28 00:00:002021-06-28 00:00:00Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-06-18 / Saudi J Biol Sci 2021 Oct;28(10):5833-5840
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-06-18 / Saudi J Biol Sci 2021 Oct;28(10):5833-58402021-06-18 00:00:002023-01-31 13:08:35Antitumor immunity enhancement through Newcastle viral oncolysate in mice model: A promising method to treat tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-06-17 / Mol Cancer Ther 2021 Sep;20(9):1723-1734
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-06-17 / Mol Cancer Ther 2021 Sep;20(9):1723-17342021-06-17 00:00:002023-01-31 13:09:00Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-06-09 / Vaccines (Basel) 2021 Jun;9(6)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-06-09 / Vaccines (Basel) 2021 Jun;9(6)2021-06-09 00:00:002021-06-09 00:00:00Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-06-04 / Cancers (Basel) 2021 Jun;13(11)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-06-04 / Cancers (Basel) 2021 Jun;13(11)2021-06-04 00:00:002021-06-04 00:00:00Immunotherapeutic Approaches in Malignant Pleural Mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-06-04 / J Clin Oncol 39, 2021 (suppl 15; abstr e14512)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-06-04 / J Clin Oncol 39, 2021 (suppl 15; abstr e14512)2021-06-04 00:00:002021-06-04 00:00:00A phase I study to evaluate the safety and effectiveness of neoantigen-based personalized dendritic cell vaccine in patients with advanced solid tumors.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-05-27 / BMC Cancer 2021 May;21(1):625
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-05-27 / BMC Cancer 2021 May;21(1):6252021-05-27 00:00:002021-05-27 00:00:00Persistent Newcastle disease virus infection in bladder cancer cells is associated with putative pro-survival and anti-viral transcriptomic changes
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-05-21 / Exp Ther Med 2021 Jul;22(1):787
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-05-21 / Exp Ther Med 2021 Jul;22(1):7872021-05-21 00:00:002023-01-31 15:58:28Modulated electro-hyperthermia with weekly paclitaxel or cisplatin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: The KGOG 3030 trial
